CN102670705A - Traditional Chinese medicine composition and application thereof - Google Patents
Traditional Chinese medicine composition and application thereof Download PDFInfo
- Publication number
- CN102670705A CN102670705A CN2012101460639A CN201210146063A CN102670705A CN 102670705 A CN102670705 A CN 102670705A CN 2012101460639 A CN2012101460639 A CN 2012101460639A CN 201210146063 A CN201210146063 A CN 201210146063A CN 102670705 A CN102670705 A CN 102670705A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- medicine composition
- calculus
- active ingredient
- renal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 84
- 239000000203 mixture Substances 0.000 title claims abstract description 23
- 206010029148 Nephrolithiasis Diseases 0.000 claims abstract description 34
- 208000000913 Kidney Calculi Diseases 0.000 claims abstract description 32
- 239000004480 active ingredient Substances 0.000 claims abstract description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- 239000007788 liquid Substances 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 239000012141 concentrate Substances 0.000 claims description 8
- 241000612166 Lysimachia Species 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 239000004575 stone Substances 0.000 claims description 5
- 208000031868 Calculus ureteric Diseases 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- 208000000014 Ureteral Calculi Diseases 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 4
- QXDMQSPYEZFLGF-UHFFFAOYSA-L calcium oxalate Chemical compound [Ca+2].[O-]C(=O)C([O-])=O QXDMQSPYEZFLGF-UHFFFAOYSA-L 0.000 claims description 4
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 4
- 239000000945 filler Substances 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 4
- 239000000314 lubricant Substances 0.000 claims description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 239000000080 wetting agent Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- CKMXBZGNNVIXHC-UHFFFAOYSA-L ammonium magnesium phosphate hexahydrate Chemical compound [NH4+].O.O.O.O.O.O.[Mg+2].[O-]P([O-])([O-])=O CKMXBZGNNVIXHC-UHFFFAOYSA-L 0.000 claims description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 229940046011 buccal tablet Drugs 0.000 claims description 2
- 239000006189 buccal tablet Substances 0.000 claims description 2
- 239000001506 calcium phosphate Substances 0.000 claims description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 2
- 235000011010 calcium phosphates Nutrition 0.000 claims description 2
- 229940095672 calcium sulfate Drugs 0.000 claims description 2
- JXRVKYBCWUJJBP-UHFFFAOYSA-L calcium;hydrogen sulfate Chemical compound [Ca+2].OS([O-])(=O)=O.OS([O-])(=O)=O JXRVKYBCWUJJBP-UHFFFAOYSA-L 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 2
- 238000004132 cross linking Methods 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 2
- 239000007938 effervescent tablet Substances 0.000 claims description 2
- 229960002442 glucosamine Drugs 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 229960001031 glucose Drugs 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 229950005770 hyprolose Drugs 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 235000019359 magnesium stearate Nutrition 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 229960001855 mannitol Drugs 0.000 claims description 2
- 229960003194 meglumine Drugs 0.000 claims description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 2
- 229940023488 pill Drugs 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 claims description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- 229910052567 struvite Inorganic materials 0.000 claims description 2
- -1 sublimed preparation Substances 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 2
- 208000002193 Pain Diseases 0.000 abstract description 12
- 230000036407 pain Effects 0.000 abstract description 11
- 206010038419 Renal colic Diseases 0.000 abstract description 6
- 241000143476 Bidens Species 0.000 abstract description 2
- 241001571764 Lysimachia christinae Species 0.000 abstract description 2
- 208000003217 Tetany Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 45
- 241000700159 Rattus Species 0.000 description 42
- 210000003734 kidney Anatomy 0.000 description 30
- 238000012360 testing method Methods 0.000 description 23
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 18
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 12
- 210000002784 stomach Anatomy 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 210000002700 urine Anatomy 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 230000008859 change Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 235000005911 diet Nutrition 0.000 description 8
- 230000037213 diet Effects 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 7
- 238000002425 crystallisation Methods 0.000 description 7
- 230000008025 crystallization Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- 229940109239 creatinine Drugs 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 6
- 238000001802 infusion Methods 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 208000006750 hematuria Diseases 0.000 description 5
- 210000000244 kidney pelvis Anatomy 0.000 description 5
- 238000010298 pulverizing process Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 206010030113 Oedema Diseases 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000003651 drinking water Substances 0.000 description 4
- 235000020188 drinking water Nutrition 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 210000000626 ureter Anatomy 0.000 description 4
- 238000012449 Kunming mouse Methods 0.000 description 3
- 208000005392 Spasm Diseases 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 230000037308 hair color Effects 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- 206010006100 Bradykinesia Diseases 0.000 description 2
- 241000530115 Clerodendrum trichotomum Species 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000006083 Hypokinesia Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000002308 calcification Effects 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 210000001624 hip Anatomy 0.000 description 2
- 230000003118 histopathologic effect Effects 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 238000002504 lithotomy Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000002445 nipple Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 210000003708 urethra Anatomy 0.000 description 2
- JGUQDUKBUKFFRO-GGWOSOGESA-N (NE)-N-[(3E)-3-hydroxyiminobutan-2-ylidene]hydroxylamine Chemical compound O\N=C(/C)\C(\C)=N\O JGUQDUKBUKFFRO-GGWOSOGESA-N 0.000 description 1
- 206010002368 Anger Diseases 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010009866 Cold sweat Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 206010020524 Hydronephrosis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241000243198 Peritrichia Species 0.000 description 1
- 235000011158 Prunus mume Nutrition 0.000 description 1
- 244000018795 Prunus mume Species 0.000 description 1
- 206010043994 Tonic convulsion Diseases 0.000 description 1
- 208000006568 Urinary Bladder Calculi Diseases 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000001557 animal structure Anatomy 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 210000000467 autonomic pathway Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000011325 biochemical measurement Methods 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000035617 depilation Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 208000022182 gross hematuria Diseases 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 206010030899 opisthotonus Diseases 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000001814 protein method Methods 0.000 description 1
- 108700001662 rat Srpra Proteins 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001034 respiratory center Anatomy 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition, which comprises a treatment active ingredient and a pharmaceutically available carrier, wherein the treatment active ingredient is prepared from the following components in weight ratio: 20-60 parts of lysimachia christinae hance and 20-60 parts of bidens pilosalinn. Proved by clinical application, the traditional Chinese medicine composition has the outstanding characteristics that renal calculi can be rapidly removed and are not easy to relapse, tetany can be resolved and pains can be relieved, and renal colic can be rapidly relieved after the traditional Chinese medicine composition is orally taken.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition that can be used as renal calculus medicine or renal calculus prophylactic agent and uses thereof.
Background technology
Along with the change with dietary habit that improves constantly of living standards of the people, the sickness rate of China's urinary system calculus is in obvious propradation.Calculus often stays in kidney, ureter, bladder and causes renal calculus, ureteral calculus, vesical calculus, and is wherein common with renal calculus.Renal calculus mostly occurred in the middle prime of life, and the male is more than the Ms.Clinical manifestation is varied, and renal calculus maybe long-term existence and asymptomatic, particularly bigger calculus.Less calculus range of activity is big, when microlith gets into UPJ or ureter, causes the wriggling that ureter is violent, discharges to impel calculus, so angor and hematuria occur.40%～50% patient is the history of pain of gapped outbreak.Pain often is positioned at waist and abdominal part, and majority is paroxysmal, also can be constant pain.Renal colic is serious lancinating pain, outbreak suddenly often, and pain often is radiated to hypogastric region, groin or burst inboard.When renal colic is serious, pale complexion, whole body is in a cold sweat, thready pulse and speed, even blood pressure drops are collapse, simultaneously with feel sick, vomiting, abdominal distention constipation.During the angor outbreak, hypourocrinia after angor is alleviated, can have the polyuria phenomenon.Hematuria is another cardinal symptom of renal calculus.During pain, often occur together gross hematuria or microscopic hematuria, in the majority with the latter, hematuria can increase the weight of after the physical exertion.The common complication of renal calculus is to block and infection, and many cases are sought medical advice because of the urinary tract infection symptom.Obstruction then can cause hydronephrosis, epigastrium or waist lump occur.
The treatment of renal calculus is main with open surgery and medicine dissolution therapy mainly.The open surgery wound is big, complication is many, and sometimes because recurrence of hepatolithiasis need go and repeatedly perform the operation and have a strong impact on renal function; Though had extracorporeal shock-wave lithotomy and some non-open operations to get the application of minimally-invasive treatment such as stone in recent years, made a lot of former miseries that need patients with surgical to exempt operation.Although extracorporeal shock-wave lithotomies etc. have brought Gospel to patient, reduced wound, the still need partner treatment of medicine of calculus behind its rubble and prevention recurrence of hepatolithiasis process, however this Western medicine medicine on the one hand is less, and is main with symptomatic treatment often, and prognosis is relatively poor.
Therefore, the practitioner begins to consider to use the Chinese medicine compound calculus, to obtain better prognosis therapeutic effect.
Herba Lysimachiae, formal name used at school: Lysimachia christinae Hance all has distribution in each province, the south of the River.Summer, Qiu Erji gather.Remove impurity, dry, cutting is given birth to and is used.Have heat-clearing and toxic substances removing, dissipating blood stasis for subsidence of swelling, the effect of dampness removing jaundice eliminating also has calculus, and is antibacterial, and antiinflammatory action all has inhibitory action to humoral immunization, cellular immunization.
Herba Bidentis Bipinnatae, formal name used at school Bidens pilosaLinn is Compositae annual herb plant.Be born in wasteland, roadside, hillside and the field of 50～3100 meters of height above sea level; Originate in the torrid zone and subtropical zone (East China, Central China, south China, each provinces and regions, southwest that comprise China) in Asia and America; Be China's medical herbs commonly used among the people, can choose the roguing grass at summer, fall flowering Sheng phase harvesting aerial parts; Using fresh herb or dry is with all herbal medicine.Water decoction that Herba Bidentis Bipinnatae and clerodendron trichotomum are mixed and made into or ethanol preserved material PARA FORMALDEHYDE PRILLS(91,95) property and albumen arthritis all have tangible antiinflammation.Single Herba Bidentis Bipinnatae or clerodendron trichotomum then do not have obvious antiinflammation.
Summary of the invention
The object of the present invention is to provide a kind of Chinese medicine composition.
Another object of the present invention provides a kind of purposes of above-mentioned Chinese medicine composition.
In order to reach above-mentioned purpose, solution of the present invention is:
A kind of Chinese medicine composition comprises treatment active ingredient and pharmaceutically available carrier, it is characterized in that said treatment active ingredient is made by following components in portion by weight: 20～60 parts of Herba Lysimachiaes, 20～60 parts of Herba Bidentis Bipinnatae.
Preferably, the mode below said treatment active ingredient is used makes: get the Herba Lysimachiae and the Herba Bidentis Bipinnatae of above-mentioned weight proportion, the back decocting is pulverized in oven dry, and decocting liquid leaves standstill, and filters, and concentrates, and must treat active ingredient.
Particularly, said treatment active ingredient adopts following mode to make: get 20～60 parts of Herba Lysimachiaes by weight ratio, 20～60 parts of Herba Bidentis Bipinnatae; Oven dry is pulverized, and mixes, and then adds the water of above-mentioned Herba Lysimachiae and 8～20 times of amounts of Herba Bidentis Bipinnatae gross weight; Soak 60～120min; Then decoct and extract 60～120min, decocting liquid leaves standstill, and is subsequent use after filtering; Medicinal residues add the water of 8～20 times of amounts again, decoct to extract 60～120min, and decocting liquid leaves standstill, and filter, and with the filtrate merging first time, concentrate, and must treat active ingredient.
Preferably, said treatment active ingredient comprises following components in portion by weight: 30～40 parts of Herba Lysimachiaes, 30～40 parts of Herba Bidentis Bipinnatae.
In the embodiment that recommends, described Chinese medicine composition is an oral formulations.
In the embodiment that recommends, said oral formulations is tablet, pill, sublimed preparation, powder, granule, powder, capsule, buccal tablet or effervescent tablet.
In the embodiment that recommends; Said carrier includes but not limited to filler, disintegrating agent, binding agent, wetting agent, lubricant, and said filler is starch, dextrin, lactose, sucrose, Icing Sugar, microcrystalline Cellulose, glucose, meglumine, glucosamine, mannitol, calcium sulfate or calcium bisulfate; Disintegrating agent is hyprolose, carboxymethyl starch sodium, polyvinylpolypyrrolidone, cross-linking sodium carboxymethyl cellulose or crosslinked hydroxypropyl methylcellulose; Binding agent is hydroxypropyl methylcellulose sodium or polyvidone; Wetting agent is water or ethanol; Lubricant is magnesium stearate or Pulvis Talci.
In addition, the applicant finds under study for action that also above-mentioned Chinese medicine composition has the purposes of prevention or treatment lithangiuria.
In the embodiment that recommends, said lithangiuria is ureteral calculus or renal calculus.
In the embodiment that recommends, said lithangiuria is calcium oxalate stone, calcium phosphate stone or struvite calculus.
Only if specialize, the implication of employed here all technology and scientific terminology is identical with the affiliated common implication of understanding of technical field those skilled in the art of the present invention.Equally, all introduce the present invention as a reference at this publication of mentioning, patent application, patent and other reference materials.
The present invention adopts and gives SD rat oral gavage 1% amine-oxides and 1% ethylene glycol making kidney of rats calculus pathological model; Then use Herba Lysimachiae and Herba Bidentis Bipinnatae to irritate stomach; Finding that above medicine has alleviates the nephridial tissue edema that causes because of calculus, slows down the damage and the pathological changes of kidney, increases voided volume; Reduce the formation of calculus in the nephridial tissue, and then prevent and treat the effect of renal calculus.Use this pharmaceutical composition of proof clinically and have fast, the difficult recurrence of calculus, but also have the distinguishing feature of relieving spasm to stop pain, oral back is alleviated renal colic fast.
The specific embodiment
Embodiment 1
Get Herba Lysimachiae 20g, Herba Bidentis Bipinnatae 20g, the oven dry pulverizing mixes, and then adds the water of above-mentioned Herba Lysimachiae and 8 times of amounts of Herba Bidentis Bipinnatae gross weight, soaks 60min, then decocts and extracts 60min, and decocting liquid leaves standstill, and the filtration back is subsequent use; Medicinal residues add the water of 8 times of amounts again, and 60min is extracted in decoction, and decocting liquid leaves standstill, and filter, and with the filtrate merging first time, concentrate, and get 4.2g treatment active ingredient.
Embodiment 2
Get Herba Lysimachiae 20g, Herba Bidentis Bipinnatae 60g, the oven dry pulverizing mixes, and then adds the water of above-mentioned Herba Lysimachiae and 20 times of amounts of Herba Bidentis Bipinnatae gross weight, soaks 120min, then decocts and extracts 120min, and decocting liquid leaves standstill, and the filtration back is subsequent use; Medicinal residues add the water of 20 times of amounts again, and 120min is extracted in decoction, and decocting liquid leaves standstill, and filter, and with the filtrate merging first time, concentrate, and get 8.6g treatment active ingredient.
Embodiment 3
Get Herba Lysimachiae 60g, Herba Bidentis Bipinnatae 20g, the oven dry pulverizing mixes, and then adds the water of above-mentioned Herba Lysimachiae and 20 times of amounts of Herba Bidentis Bipinnatae gross weight, soaks 120min, then decocts and extracts 120min, and decocting liquid leaves standstill, and the filtration back is subsequent use; Medicinal residues add the water of 20 times of amounts again, and 120min is extracted in decoction, and decocting liquid leaves standstill, and filter, and with the filtrate merging first time, concentrate, and get 8.5g treatment active ingredient.
Embodiment 4
Get Herba Lysimachiae 30g, Herba Bidentis Bipinnatae 40g, the oven dry pulverizing mixes, and then adds the water of above-mentioned Herba Lysimachiae and 20 times of amounts of Herba Bidentis Bipinnatae gross weight, soaks 120min, then decocts and extracts 120min, and decocting liquid leaves standstill, and the filtration back is subsequent use; Medicinal residues add the water of 20 times of amounts again, and 120min is extracted in decoction, and decocting liquid leaves standstill, and filter, and with the filtrate merging first time, concentrate, and get 7.6g treatment active ingredient.
Embodiment 5
Get Herba Lysimachiae 40g, Herba Bidentis Bipinnatae 30g, the oven dry pulverizing mixes, and then adds the water of above-mentioned Herba Lysimachiae and 12 times of amounts of Herba Bidentis Bipinnatae gross weight, soaks 100min, then decocts and extracts 100min, and decocting liquid leaves standstill, and the filtration back is subsequent use; Medicinal residues add the water of 12 times of amounts again, and 100min is extracted in decoction, and decocting liquid leaves standstill, and filter, and with the filtrate merging first time, concentrate, and get 7.8g treatment active ingredient.
Experimental animal pharmacodynamics provided by the invention, clinical practice result and acute toxicity test concrete grammar step are following:
Test Example 1:Medicine of the present invention is to the control test of renal calculus rat model
Method: adopt ethylene glycol to add ammonium chloride method and induce kidney of rats calculus model, give medicine simultaneously and carry out the intervention treatment, observe the calculus degree of medicine, serum BUN, the influence of Cr content and 24 hours voided volume to kidney of rats calculus model.
1 test material
Animal: the SD rat, the cleaning level, body weight 180～200g, male, health, Shanghai Slac Experimental Animal Co., Ltd..
The treatment active ingredient (trial drug) that obtains among medicine: the embodiment 5, PAISHI KELI contains 11g crude drug/g, Jisheng Pharmaceutical Factory, Nanchang, Jiangxi system.
Reagent: creatinine reagent box, blood urea nitrogen test kit, it is made that bio-engineering research is built up in Nanjing.
Instrument: SpectraMAX M2 ELIASA (Molecular Device company), electronic balance (Mettler Toledo Inc.), operating microscope, thermostat water bath.
2 test methods
2. 1 modeling and index detect
60 of rats, adaptability are divided into 6 groups after raising for 1 week at random, 10 every group, are respectively normal control group, model control group, positive drug (PAISHI KELI) matched group and the large, medium and small dose groups of trial drug.Irritating stomach every day except that the normal control group gives the distilled water 10ml/kg; (every day is all with containing tap water that 1% ethylene glycol adds 1% ammonium chloride as drinking water in all the other 5 groups of rat modelings; Drink to change into drinking separately after a week and contain 1% ethylene glycol); Simultaneously to positive drug control group and the large, medium and small dose groups of trial drug by positive drug control group (6g crude drug/kg), the heavy dose of group of trial drug (6g crude drug/kg), middle dose groups (4g crude drug/kg), small dose group (the dosage gastric infusion of 2g crude drug/kg); Model control group is irritated stomach and is given distilled water, and each treated animal administration capacity is 10ml/kg, continuously modeling and 4 weeks of gastric infusion.Test and carry out 14d, rat docking blood sampling, the centrifuging and taking upper serum is used for biochemical measurement: diacetyl-oxime colorimetry is surveyed serum urea nitrogen (BUN) level, is removed protein method survey creatinine (Crea) level.Test is carried out 28d and is collected each rat 24h urine on an empty stomach respectively with metabolic cage, measures the 24h voided volume.Get the both sides kidney after rat is put to death and weigh, calculate the organ coefficient of kidney.Every rat is got right kidney, and 10% formalin is fixed, and is used for the nephridial tissue pathological examination.
2. 2 nephridial tissue histopathologic examinations
Criterion is following:
0 grade: no crystallization;
1 grade: the renal cortex intercrystalline;
2 grades: the renal medulla intercrystalline;
3 grades: the renal papillae intercrystalline;
4 grades: the renal pelvis intercrystalline.
Be designated as 1,2,3,4 respectively, 5 minutes.Each administration group result of the test and model control group are organized a t inspection statistics and are handled.
3 results
3. 1 trial drug is to the influence of calculus rat blood serum blood urea nitrogen, creatinine.
The result sees table 1.
With the normal control group relatively, renal calculus model group rat blood serum blood urea nitrogen, creatinine significantly increase (P < 0.001); With model control group relatively, the heavy dose of group of trial drug rat blood serum blood urea nitrogen obviously reduces (P < 0.05～0.001) with creatinine level, also obviously reduction of middle dose groups rat blood serum urea nitrogen content (P < 0.05).
Table l trial drug is to the influence of large mouse with renal calculs serum urea nitrogen, creatinine
Compare with model, * P 0.05, * * P < 0.0l, * * * P < 0.001
3. 2 trial drugs are to the influence of calculus rat kidney weight, 24h voided volume, renal calculus degree
The result sees table 2.
With model control group relatively, heavy dose of group kidney coefficient significantly reduces, the 24h voided volume significantly increases (p < 0.05～0.001).Heavy dose of group, middle dose groups renal calculus degree obviously alleviate (p < 0.001).
Table 2 trial drug is to the influence of calculus rat kidney coefficient, 24h voided volume, renal calculus degree
Compare with model, * P 0.05, * * P 0.01, * * * P < 0.001
3.3 trial drug influences calculus kidney of rats histology
Mirror is observed visible down: normal rats kidney surface color is even, and the boundary of cortex medullary substance is clear, no calcium oxalate crystal in the tangent plane; Model control group rat kidney surface irregularity has obvious calcification speckle, forms some bulk granule dress calculus in the renal pelvis; The crystallization of the large, medium and small dose groups nephridial tissue of trial drug then mainly is scattered single kitchen range property and the distribution of local number special mess property; The visible crystallization of positive controls is in renal cortex, medullary substance, nipple and being dispersed in property of renal pelvis place or the assembly of many kitchen ranges property.
3.4 ordinary circumstance is observed
Normal rats hair color gloss, honey stomach, the drinking-water appropriateness, weight increase is very fast, and stool is graininess, and the twenty-four-hour urine amount is normal, and the urine color is yellowish.Modeling is respectively organized rat and lassitude occurred, bradykinesia, and hair is owed gloss, and diet reduces, and activity is few, and hematuria symptom, loose stool appear in indivedual rats.The urine amount then appears in the treatment group to be increased, and spiritual diet activity is normal basically, the mental status of rat in the trial drug group wherein, and active situation, diet and voided volume all are superior to the PAISHI KELI group.
Conclusion
1. trial drug has the effect that prevents and treats the kidney of rats calculus; Its mechanism of action possibly alleviate the damage of renal cells with it and promote its reparation; Strengthen nephridial tissue organelle Stability Analysis of Structures, reduce inflammatory cell infiltration, strengthen pelviureteral wriggling; Quicken urine excretion, enhancing urine mobilization force etc. are relevant.
2. trial drug is basic identical to the preventive and therapeutic effect and the PAISHI KELI of kidney of rats calculus model, but its whole curative effect is superior to PAISHI KELI, and pointing out this medicine is the active drug of preventing and treating renal calculus.
Test Example 2: medicine of the present invention is to the therapeutic test of renal calculus rat model
Method: adopt ethylene glycol to add ammonium chloride method and induce kidney of rats calculus model, give medicine behind the modeling 14d and treat, the viewing test medicine is to the calculus degree of kidney of rats calculus model, the influence of 24 hours voided volume.
1 test material
Animal: the SD rat, the cleaning level, body weight 180～200g, male, health, Shanghai Slac Experimental Animal Co., Ltd..
The treatment active ingredient (trial drug) that obtains among medicine: the embodiment 4, PAISHI KELI contains 11g crude drug/kg, Jisheng Pharmaceutical Factory, Nanchang, Jiangxi system.
Instrument: SpectraMAX M2 ELIASA (Molecular Device company), electronic balance (prunus mume (sieb.) sieb.et zucc. Teller one holder benefit company), operating microscope, thermostat water bath.
2 test methods
2. 1 modeling and index detect
36 of rats, adaptability are divided into 6 groups after raising for 1 week at random, 6 every group, are respectively normal control group, model control group, positive drug (PAISHI KELI) matched group, the large, medium and small dose groups of trial drug.5 groups of rat modelings (every day is all with containing tap water that 1% ethylene glycol adds 1% amine-oxides as drinking water); Stop modeling behind the modeling 14d; The normal control group is irritated stomach and give distilled water 10ml/kg every day; Simultaneously to positive drug control group and the large, medium and small dose groups of trial drug by positive drug control group (6g crude drug/kg), the heavy dose of group of trial drug (6g crude drug/kg), middle dose groups (4g crude drug/kg), small dose group (the dosage gastric infusion of 2g crude drug/kg); Model control group is irritated stomach and is given distilled water, and each treated animal administration capacity is 10ml/kg.Continuous gastric infusion 7d.8d is carried out in test, collects each rat 24h urine on an empty stomach respectively with metabolic cage, measures the 24h voided volume.Get the both sides kidney after rat is put to death and weigh, calculate the organ coefficient of kidney.Every rat is got right kidney, and 10% formalin is fixed, and is used for the nephridial tissue pathological examination.
2.2 nephridial tissue histopathologic examination
Criterion is following:
0 grade: no crystallization;
1 grade: the renal cortex intercrystalline;
2 grades: the renal medulla intercrystalline;
3 grades: the renal papillae intercrystalline;
4 grades: the renal pelvis intercrystalline.
Be designated as 1,2,3,4 respectively, 5 minutes.Each administration group result of the test and model control group are organized a t inspection statistics and are handled.
3 results
3. 1 trial drug is to the influence of calculus rat kidney coefficient, 24h voided volume, renal calculus degree.
The result sees table 3.
With model control group relatively, heavy dose of group kidney coefficient significantly reduces (P < 0.05～0.01), heavy dose of group, middle dose groups renal calculus degree obviously alleviate (P < 0.001).Urine calcium ion and twenty-four-hour urine amount do not have significant change.
Table 3 trial drug is to the influence of calculus rat kidney coefficient, 24h voided volume, renal calculus degree
Compare with model, * P 0.05, * * P 0.01, * * * P < 0.001
3.2 trial drug influences calculus kidney of rats histology
Mirror is observed visible down: normal rats kidney surface color is even, and the boundary of cortex medullary substance is clear, no calcium oxalate crystal in the tangent plane; Model control group rat kidney surface irregularity has obvious calcification speckle, and nephridial tissue changes and mainly forms the crystallization of many kitchen ranges property at renal medulla cone collecting tubule and renal papillae place; The crystallization of the large, medium and small dose groups nephridial tissue of trial drug then mainly is scattered single kitchen range property and the distribution of local number special mess property; The visible crystallization of positive control elder sister is in renal cortex, medullary substance, nipple and being dispersed in property of renal pelvis place or the assembly of many kitchen ranges property.
3.3 ordinary circumstance is observed
Normal rats hair color gloss, honey stomach, the drinking-water appropriateness, weight increase is very fast, and stool is graininess, and the twenty-four-hour urine amount is normal, and the urine color is yellowish.Modeling is respectively organized rat and lassitude occurred, bradykinesia, and hair is owed gloss, and diet reduces, and activity is few, loose stool.The then spiritual diet activity of treatment group is normal basically.
Conclusion
1 trial drug can reduce the formation of calculus in the nephridial tissue, and the kidney of rats calculus is had obvious therapeutic action.
2 these medicines are basic identical to the therapeutical effect and the PAISHI KELI of kidney of rats calculus model.
Test Example 3: the The acute toxicity tests report
The amounts of reactants of test determination is: the maximum dosage-feeding test
Maximum dosage-feeding test is meant in single or the 24h the maximum dosage that repeatedly (2～3 times) administration is adopted.The maximum dosage-feeding test is meant and under the condition of rational administration concentration and rational administration capacity, gives experimental animal with the maximal dose that allows, observes the reaction that animal occurs.
1 test method
1.1 tried thing
The mixing water that is tried thing and the be Herba Lysimachiae+Herba Bidentis Bipinnatae liquid of boiling medicine.
Method for distilling: Herba Lysimachiae 100g+ Herba Bidentis Bipinnatae 100g, add water 4000ml (1:20) after the mixing and carry out the decocting extraction, to filter, filtrating is deposited fully; Medicinal residues add with water by volume the same terms extraction 1 time, filter, and merge and vacuum concentration with the 1st extracting solution, get dry thing 26g.
Reagent preparation: adopt dissolved in distilled water, be made into the drug solution that maximum meltage is 1.73g/ml.
Being converted into the crude drug dosage is: 266.67g crude drug/kg body weight.
1.2 experimental animal
Adopt healthy adult KM mice, male and female half and half.Average weight 25g.The initial body weight of animal is no more than average weight ± 20%.
1.3 test is divided into groups
This test is provided with 2 groups, and 10 every group, male and female half and half are divided into blank control group, administration group at random.
Irritate 3 distilled water solutions of stomach in blank control group: the 24h.
Irritate stomach in administration group: the 24h and receive reagent thing solution for 3 times.
1.4 route of administration
Take the method for gastric infusion.
1.5 administration capacity
It is 20ml/kg that gastric infusion, mice are irritated the stomach amount at every turn.
1.6 observe the time limit
Be 14 days observing time.
1.7 observation index
Comprise the weight of animals variation, diet, outward appearance, behavior, secretions, Excreta, death condition and toxic reaction (symptom of toxic reaction, the order of severity, zero-time, persistent period, whether reversible) etc.Dying and dead animal are in time dissected, and other animals are dissected after the observation period finishes, the change of observation animal organ's volume, color, quality.
2 interpretations of result
All there is not death 2.1 respectively organize mice.
2.2 diet: it is all normal that each organizes the mice diet situation.
2.3 outward appearance: each organizes mice hair color and glossiness no significant difference, does not have perpendicular hair, depilation phenomenon, no edema or erythema, and prompting is not had obviously renal function by the reagent thing to be influenced, skin not to be produced inflammation, allergic phenomena.
2.4 breathe: each organize mice all do not have pant, the cyanosis phenomenon, prompting receive the reagent thing to respiratory center, cardio-pulmonary function does not have obviously influences.
2.5 behavior: it is normal that each organizes the mice behavior, atremia, clonicity tic, tonic convulsion, dusk fault property tic, and no opisthotonus does not have irascible behavior.Prompting receive the reagent thing to central nervous system, breathing, neuromuscular, autonomic nerve does not have obviously influences.
2.6 the pain sensation: each organizes the equal analgesia forfeiture of mice phenomenon.
2.7 vomiting: each organizes mice does not all have vomiting or retch phenomenon.
2.8 secretions: it is all normal that each organizes mice, do not have the moist phenomenon of mouthful peritricha.
2.9 Excreta: administration occurred voiding excreta moist glutinous greasy the same day, and stool colour is a brown, no polyuria, redly urinate, the urinary incontinence phenomenon.After this drain normal.
2.10 dissect:
Liver: the liver color and luster has no significant change, and does not have obvious enlargement and form and changes.
Kidney: kidney does not have the edema phenomenon, does not have obviously to change.
Heart: do not have obviously change.
Lungs: do not have obviously change.
Spleen: do not have obvious ripple and become.
Conclusion: receive the reagent thing in this maximum dosage-feeding test, the KM mice is not produced tangible toxicity phenomenon.
Test Example 4: the clinical treatment result
Complete documentation treatment renal calculus patient 62 people (calculus of urethra 23 people wherein, two renal calculus 24 people, single renal calculus 15 people are arranged at present.These patients have B ultrasonic/X line to take the photograph sheet as the contrast before and after the treatment).
Everyone takes this medical herbs (weight proportion of Herba Lysimachiae and Herba Bidentis Bipinnatae is 1:1) and pulverizes the powder of processing (60g/ bag), and wrap every day one, and decocting is repeatedly worked as tea-drinking, two courses of treatment Monday, shared two courses of treatment.
The result: renal calculus effective percentage first course of treatment accounts for 80% (containing two renal calculuss), second the course of treatment effective percentage be more than 90%.Calculus of urethra effective percentage first course of treatment is 95%.
In addition, this decoct also has the distinguishing feature of relieving spasm to stop pain, and renal colic can be alleviated in 5～10 minutes in oral back.
Model case:
Bag X, man, 30 years old.Suffered from right renal calculus 3 years, ultrasound diagnosis finding " right side renal calculus (the about 5mm*4mm of size), companion's sinus renalis slightly separates " is taken 2 weeks of this medicine, and calculus excretes.Check B ultrasonic once more, do not see obviously unusual.
Old X, man, 46 years old.Suffer from 2 weeks of ureteral calculus, pain unbearably, ultrasound diagnosis finding " left ureter basin section calculus, the about 4mm*6mm of size ", pain disappears half an hour behind oral the medicine, one week the back calculus per urethram excrete, check B ultrasonic once more, recover normally.
In sum; The present invention shows through a large amount of experimental studies; The Chinese herbal medicine formula of being made up of Herba Lysimachiae and Herba Bidentis Bipinnatae has and alleviates the nephridial tissue edema that causes because of calculus, slows down the damage and the pathological changes of kidney, increases voided volume; Reduce the formation of calculus in the nephridial tissue, and then can prevent or treat renal calculus.In the maximum dosage-feeding test, the KM mice is not produced tangible toxicity phenomenon.This decoct of clinical practice proof has fast, the difficult recurrence of calculus, but also has the distinguishing feature of relieving spasm to stop pain, and oral back is alleviated renal colic fast.
Above Chinese herbal medicine formula is evident in efficacy, and safety range is big, and technology is simple, and integrated cost is low, is a kind of medicine that can be used for preventing and mooring the renal calculus of treatment.
The foregoing description is a preferred implementation of the present invention; But embodiment of the present invention is not restricted to the described embodiments; Other any do not deviate from change, the modification done under spirit of the present invention and the principle, substitutes, combination, simplify; All should be the substitute mode of equivalence, be included within protection scope of the present invention.
Claims (9)
1. a Chinese medicine composition comprises treatment active ingredient and pharmaceutically available carrier, it is characterized in that said treatment active ingredient is made by following components in portion by weight: 20～60 parts of 20～60 parts of Herba Lysimachiaes and Herba Bidentis Bipinnatae.
2. according to the Chinese medicine composition described in the claim 1, it is characterized in that: the mode below said treatment active ingredient is used makes: get the Herba Lysimachiae and the Herba Bidentis Bipinnatae of above-mentioned weight proportion, the back decocting is pulverized in oven dry; Decocting liquid leaves standstill; Filter, concentrate, must treat active ingredient.
3. according to the Chinese medicine composition described in the claim 1, it is characterized in that: said treatment active ingredient comprises following components in portion by weight: 30～40 parts of Herba Lysimachiaes, 30～40 parts of Herba Bidentis Bipinnatae.
4. according to the Chinese medicine composition described in the claim 1, it is characterized in that: described Chinese medicine composition is an oral formulations.
5. according to the Chinese medicine composition described in the claim 4, it is characterized in that: said oral formulations is tablet, pill, sublimed preparation, powder, granule, powder, capsule, buccal tablet or effervescent tablet.
6. according to the Chinese medicine composition described in the claim 1; It is characterized in that: said carrier includes but not limited to filler, disintegrating agent, binding agent, wetting agent, lubricant, and said filler is starch, dextrin, lactose, sucrose, Icing Sugar, microcrystalline Cellulose, glucose, meglumine, glucosamine, mannitol, calcium sulfate or calcium bisulfate; Disintegrating agent is hyprolose, carboxymethyl starch sodium, polyvinylpolypyrrolidone, cross-linking sodium carboxymethyl cellulose or crosslinked hydroxypropyl methylcellulose; Binding agent is hydroxypropyl methylcellulose sodium or polyvidone; Wetting agent is water or ethanol; Lubricant is magnesium stearate or Pulvis Talci.
7. claim 1 or 2 or 3 or 4 or 5 or 6 the Chinese medicine composition purposes in preparation prevention or treatment lithangiuria medicine.
8. according to the purposes described in the claim 7, it is characterized in that: said lithangiuria is ureteral calculus or renal calculus.
9. according to the purposes described in the claim 7, it is characterized in that: said lithangiuria is calcium oxalate stone, calcium phosphate stone or struvite calculus.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012101460639A CN102670705A (en) | 2012-05-14 | 2012-05-14 | Traditional Chinese medicine composition and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012101460639A CN102670705A (en) | 2012-05-14 | 2012-05-14 | Traditional Chinese medicine composition and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102670705A true CN102670705A (en) | 2012-09-19 |
Family
ID=46803691
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012101460639A Pending CN102670705A (en) | 2012-05-14 | 2012-05-14 | Traditional Chinese medicine composition and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102670705A (en) |
-
2012
- 2012-05-14 CN CN2012101460639A patent/CN102670705A/en active Pending
Non-Patent Citations (1)
| Title |
|---|
| 汤迎爽等: "鬼针草的化学成分与药理作用研究进展", 《中医药导报》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101406635B (en) | Chinese medicine decoction for treating stranguria and eliminating stone | |
| KR100743979B1 (en) | Herbal composition for treatment of chronic renal failure and method to produce thereof | |
| CN101757591B (en) | Traditional Chinese medicine composition for treating chronic colitis and protitis | |
| CN109224039B (en) | Chinese medicinal composition for treating kidney fibrosis and tonifying kidney | |
| CN101317881A (en) | Traditional Chinese Medicine Shencha Paishi Compound and Its Preparation | |
| CN102106993B (en) | Traditional Chinese medicine composition for treating fatty liver and preparation method thereof | |
| CN101433649A (en) | Composition for treating gall stone symptom | |
| CN102670705A (en) | Traditional Chinese medicine composition and application thereof | |
| CN104971319B (en) | A kind of drug and preparation method thereof for treating kidney stone | |
| CN108686102A (en) | A kind of Chinese medicine composition for treating gout | |
| CN107693732A (en) | A kind of pharmaceutical composition for treating hypertensive nephropathy and preparation method thereof | |
| CN102895444A (en) | Traditional Chinese medicine composition for treating lithangiuria | |
| CN106963912A (en) | It is a kind of to treat dalbergia wood compound of eczema and preparation method thereof | |
| CN102552767B (en) | Traditional Chinese medicine for treating kidney stone, preparation method and administration mode | |
| CN102949458A (en) | Traditional Chinese medicine composition for treating or preventing lithangiuria, and applications thereof | |
| CN100367997C (en) | Medicine for treating arthrolithiasis and preparing method thereof | |
| CN104800675A (en) | Medicament for treating active ulcerative colitis | |
| CN103948767A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, as well as preparation method and application thereof | |
| CN110463799A (en) | A kind of wild plant composition of protect liver constipation-relieving tea | |
| CN116712472B (en) | Traditional Chinese medicine composition for treating urinary calculus, preparation method and application thereof | |
| CN102836365A (en) | Chinese medicinal composition for treating urinary system calculi and application thereof | |
| CN105749021A (en) | Chinese medicine preparation for treating chronic glomerulonephritis | |
| CN117462611A (en) | A traditional Chinese medicine composition for treating early diabetic nephropathy and its preparation method | |
| CN101601840A (en) | A kind of medicine for the treatment of hepatolenticular degeneration | |
| CN106038812A (en) | Traditional Chinese medicine capsule for reducing blood fat and removing atherosclerotic plaque |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: ZHENG HUAGUI Free format text: FORMER OWNER: ZHANG ZICHENG Effective date: 20130221 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent of invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Zheng Huagui Inventor after: Zhang Zicheng Inventor after: Jin Xin Inventor after: Su Zhengqin Inventor before: Zhang Zicheng Inventor before: Zheng Huagui Inventor before: Jin Xin Inventor before: Su Zhengqin |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: ZHANG ZICHENG ZHENG HUAGUI JIN XIN SU ZHENGQIN TO: ZHENG HUAGUI ZHANG ZICHENG JIN XIN SU ZHENGQIN |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20130221 Address after: Town Park Road 355400 Ningde City Zhouning County in Fujian province No. 8 Lions Applicant after: Zheng Huagui Address before: The source of the town of Ningde city in Fujian province 355400 Zhouning County Pu Yang Cun 85 Road No. 25 Applicant before: Zhang Zicheng |
|
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20120919 |